Kiniksa (KNSA) CFO Grants 12,275 RSUs and 39,363-Share Option; Sales Reported
Rhea-AI Filing Summary
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported multiple equity transactions on Form 4 covering September 1-2, 2025. The filing shows grant activity including 12,275 Restricted Share Units (RSUs), a 39,363-share option with a $33.49 exercise price and several additional RSU grants and awards. It also discloses sales of Class A Ordinary Shares: 2,920 shares sold at $33.49 and 900 shares sold at $34.28. Following the reported transactions, the filing lists varying beneficial ownership totals for each line item, with direct ownership reported for all items. The form is signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Significant equity grants: 12,275 RSUs and a 39,363-share option, providing long-term incentive alignment
- Clear vesting schedules: RSUs vest 25% annually over four years and the option vests over multi-year schedule through 2035
- Grants documented as direct ownership, simplifying ownership tracing
Negative
- Reported share disposals: 2,920 shares sold at $33.49 and 900 shares sold at $34.28, reducing direct holdings on specific lines
- Option exercise price of $33.49 may be near recent sale prices, indicating limited immediate intrinsic value if market price declined below that level (based solely on filing prices)
Insights
TL;DR: CFO received compensation in the form of RSUs and an option while executing small share disposals at ~$33–$34 per share.
The Form 4 documents routine equity compensation and limited open-market sales by the reporting CFO. Key items are a 39,363-share option exercisable at $33.49 and 12,275 RSUs granted with multi-year vesting schedules. The sales (2,920 shares at $33.49 and 900 shares at $34.28) reduced direct holdings reported on specific lines. Vesting schedules span four years for RSUs and standard multi-year vesting for the option, indicating retention-linked compensation rather than immediate liquidity events. No changes to derivative ownership counts beyond the documented grants are indicated.
TL;DR: Transactions reflect standard executive compensation grants with documented vesting; limited sales were reported contemporaneously.
The disclosure provides clear grant terms: RSUs generally vest over four years with 25% annual vesting and the option vests 25% after one year then monthly thereafter through 2035. These are typical structures to align executive incentives with long-term shareholder value. The filing also reports contemporaneous sales at market prices which are recorded separately. All reported holdings are direct. The form is properly executed by an attorney-in-fact, consistent with procedural norms for insiders.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 1,861 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 1,861 | $0.00 | -- |
| Tax Withholding | Class A Ordinary Share | 900 | $34.28 | $31K |
| Grant/Award | Restricted Share Unit | 12,275 | $0.00 | -- |
| Grant/Award | Share Option | 39,363 | $0.00 | -- |
| Exercise | Restricted Share Unit | 1,592 | $0.00 | -- |
| Exercise | Restricted Share Unit | 1,750 | $0.00 | -- |
| Exercise | Restricted Share Unit | 2,694 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 1,592 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 1,750 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 2,694 | $0.00 | -- |
| Tax Withholding | Class A Ordinary Share | 2,920 | $33.49 | $98K |
Footnotes (1)
- Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.
